Biotech Stock Screen for 2026
The biotechnology industry is characterized by rapid innovation and high growth potential, making it an attractive area for investment. This screen identifies leading biotech stocks for 2026, emphasizing companies at the forefront of medical advancements. The focus is on firms that are developing novel therapeutics and diagnostics, and that are likely to achieve significant milestones in the coming year.
Names rising to the top of the screen
The strongest names remain easy to scan without losing the valuation context behind the ranking.
| # | Ticker | Company | AI Score | Price | Change | Market Cap | P/E |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech, Inc. | 98 | $345.55 | -0.73% | $10.2B | 41.8 |
| 2 | INCY | Incyte Corporation | 98 | $123.28 | -2.17% | $25.0B | 15.2 |
| 3 | EXEL | Exelixis, Inc. | 98 | $56.20 | -2.14% | $14.4B | 17.5 |
| 4 | ARGX | argenx SE | 97 | $984.04 | -1.82% | $61.2B | 36.0 |
| 5 | HRMY | Harmony Biosciences Holdings, Inc. | 97 | $41.10 | -1.25% | $2.4B | 13.1 |
| 6 | UTHR | United Therapeutics Corporation | 97 | $503.86 | -0.58% | $21.4B | 16.7 |
| 7 | HALO | Halozyme Therapeutics, Inc. | 96 | $107.00 | -0.36% | $12.7B | 30.4 |
| 8 | VRTX | Vertex Pharmaceuticals Incorporated | 96 | $514.90 | +0.07% | $130.6B | 29.7 |
| 9 | LGND | Ligand Pharmaceuticals Incorporated | 95 | $284.47 | -1.65% | $5.8B | 28.9 |
| 10 | INVA | Innoviva, Inc. | 94 | $20.56 | -0.29% | $1.5B | 4.2 |
| 11 | REGN | Regeneron Pharmaceuticals, Inc. | 94 | $793.26 | -1.78% | $81.7B | 18.9 |
| 12 | TECH | Bio-Techne Corporation | 93 | $72.35 | +0.37% | $11.3B | 61.6 |
Where valuation pressure is clustering
Healthcare100%
Shortlist Context
This shortlist is designed for investors seeking exposure to the biotech sector through companies with strong growth prospects. The selected stocks represent firms that are actively advancing medical science and are expected to deliver significant value through their innovative products and therapies. This list offers a focused view of biotech companies that may lead the market in 2026.
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
Questions worth resolving before acting on the screen
What makes a biotech stock 'best' for 2026?
The designation relies on pipeline strength, clinical advancements, and potential market impact of therapies. Financial health and strategic positioning also contribute.
How often is this biotech stock list updated?
The list is updated annually to reflect changes in clinical trial outcomes, regulatory milestones, and market conditions.
What are the risks of investing in biotech stocks?
Biotech investments involve high risk due to clinical trial failures, regulatory hurdles, and competition. Diversification and due diligence are essential.
Can small-cap biotech stocks be considered 'best'?
Yes, small-cap biotechs with promising technology or therapies can be included, based on their growth potential and innovation.